Looking forward to present the results of #botensilimab in patients with #OvarianCancer at #SGO23 in Tampa. BIDMC Harvard Medical School #Immunotherapy

We’re proud to announce positive data showing a 33% overall response rate for our novel multifunctional #CTLA4 #botensilimab in combination with #balstilimab in recurrent platinum refractory/resistant #OvarianCancer. Learn more: investor.agenusbio.com/news-releases/…

PD-1/CTLA-4 Combination Drives Progress Across Tumor Types Bruno Bockorny MD FACP Ben Schlechter BIDMC Harvard Medical School Dana-Farber #oncology ow.ly/tn5B50NJh2Q

Agenus Receives Fast Track Designation for Botensilimab and Balstilimab in Colorectal Cancer. Read here: investor.agenusbio.com/news-releases/…

Thanks for highlighting, was a great group effort. Michael Postow Memorial Sloan Kettering Cancer Center @drmoniquetello Joe Grossman #mikedougan Journal of Clinical Oncology

Botensilimab plus balstilimab improves outcomes in recurrent platinum-resistant/-refractory ovarian cancer. clinicaloncology.com/Solid-Tumors/A… SGO Bruno Bockorny MD FACP Society for Immunotherapy of Cancer

Today, Dr. Andrea Bullock presented positive data showing the survival benefit of botensilimab & balstilimab in #patients with advanced #colorectalcancer. Learn more here: investor.agenusbio.com/news-releases/… BIDMC #WCGIC23

Neoadjuvant botensilimab plus balstilimab response pattern in locally advanced mismatch repair proficient colorectal cancer | Oncogene nature.com/articles/s4138…

🆕🗞️Just out 🪺#NEST-1 trial results👇🏾 Are we on the verge of a new drug combo for colon or rectal cancer? Substantial & brisk responses to just☝🏾dose of BOT🟢➕BAL🔹🔹 immunotherapy.🙌🏾 Pattern & kill is unprecedented🌊. ASCO #GI24 OncoAlert Abstract 117📍Poster Board H2

Botensilimab and balstilimab in MSS CRC, just out in Nature Medicine: nature.com/articles/s4159…

Results from our Phase 1 clinical trial on the combination of botensilimab and balstilimab for MSS mCRC have been published in Nature Medicine. Read the full publication here: go.nature.com/4enyRla

From the December issue: Botensilimab, an Fc-enhanced anti-CTLA-4 antibody, Is Effective Against Tumors Poorly Responsive to Conventional Immunotherapy bit.ly/4gqFUKh By Dhan Chand and colleagues Agenus

🆕#GI25 abstracts now released! 📰 🗞️ Neoadjuvant #immunotherapy continues to impress! Building upon the paradigm shift of immunotherapy to earlier settings ➡️📈CURES🙌🏽 ✅NEST🪺 ✅UNICORN🦄 ✅NICHE These trials📚~80 treated. ✔️SAFE. 🔜Time for a phase-2/3. OncoAlert #CRCSM

#GI25 Neoadjuvant immunotherapy for MSS storms the stage. Amazing responses to Bot + Bal Agenus Can’t wait for the Phase III (or a accelerated approval; I can dream) This will be a game changer for MSS CRC. Congrats Pashtoon Kasi MD, MS

Today, at GI ASCO, I had the privilege of presenting the results of R Phase 2 study of BOT +/- BAL in chemoresistant MSS CRC- an area in dire need of treatment options. BOT75/BAL240 ORR 19%, DCR 55%. BAL value confirmed. Majority study responses ongoing. DURABLE responses matter

GI/ASCO: We presented our Phase 1 BOT/BAL with FOLFOX in MSS MCRC. 14 patients on the phase 1 study. 10 had prior Ox and 12 had prior chemo, yet ORR was 10/14 patients (majority of the pts had liver mets). The combination was safe with 2 doses of BOT + Q2w FOLFOXBEV/BAT

✅ BOT/BAL IST data in the neoadjuvant colon setting @#GI25 ! 🚨mPR & pCR rates acheived and confirmed now in 2 independent trials pave the way for next generation clinical trial designs for our pts. let’s change the course of CRC together👏🏽👏🏽GONO Foundation Manish A. Shah ASCO

🎤 Elisa Fontana (UK) intervista Filippo Ghelardi (IT) sui risultati di GONO UNICORN: solo 1 ciclo con il nuovo anti-CTLA4 botensilimab + anti-PD1 balstilimab dà risposte maggiori o complete nel cancro del colon MSS e 93% di eradicazione completa in MSI.#GI25 #Oncology

🚨 NEW in Journal of Clinical Oncology shows promise for advanced sarcomas Combining #BOT/#BAL: ✅ ORR: 19.2% (all sarcomas) ✅ ORR: 27.8% (angiosarcoma) ✅ Durable responses: 21.7 months median DOR ✅ Manageable safety Kudos to Dr. Breelyn Wilky, MD 🎗 , Agenus & team ascopubs.org/doi/10.1200/JC…

Today at #AACR25, Dr. Myriam Chalabi presented the first results from the NEOASIS study, evaluating neoadjuvant botensilimab/balstilimab in early-stage MSS and MSI-H cancers, including colorectal and breast cancers. Learn more: bit.ly/3GGTiwM. #Oncology #ClinicalTrial